Comment
Author: Admin | 2025-04-28
Officer and as a director since 1992. He joined Zonagen in 1989 as Vice President of Operations. Previously, Podolski spent twelve years in various engineering, product development and manufacturing positions at G.D. Searle, a subsidiary of Monsanto Company. Before joining Monsanto, Podolski held positions in manufacturing, engineering, quality control and development of fine chemicals, antibiotics, pharmaceuticals and hospital products with Abbott Laboratories, Dearborn Chemical Company and Baxter Pharmaceuticals. Joseph S. Podolski,[1] the man who led Zonagen through two decades, decided it was time for a name change. In 2006, Zonagen changed its name to Repros Therapeutics, started to develop other pharmaceutical products for the reproductive system, and began work on its fourth lead drug, Proellex. Proellex is a very similar drug to asoprisnil. Asoprisnil was developed by Germany-based Schering AG to treat endometriosis. Development was discontinued because the drug was causing thickening of the endometrium. Repros claimed that its time on the drug/off the drug approach will make a big difference in safety versus asoprisnil. Currently, products under clinical trial are Proellex and Androxal. None have been approved by the Food and Drug Administration as of mid-2010. Androxal consists of an isomer of Clomifene, which is already being used as a generic treatment for male hypogonadism.In December 2017, Allergan announced it was buying Repros Therapeutics.[3] Repros now operates as a subsidiary of Allergan.[4]^ a b "Joseph S. Podolski Profile - Forbes.com". people.forbes.com. Archived from the original on 4 September 2010. Retrieved 15 January 2022.^ Brian Wallstin, Biological Disaster, Houston Press (Aug 20 1998)^ Inc, Repros Therapeutics (12 December 2017). "Repros Therapeutics Inc.® Announces Acquisition by Allergan plc". GlobeNewswire News Room (Press release). ^ "Repros Therapeutics Inc". www.bloomberg.com.Official websiteHistorical business data for Repros Therapeutics:SEC filings
Add Comment